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Treating Patients with Hemiplegic
Shoulder Pain
ABSTRACT
Snels IAK, Dekker JHM, van der Lee JH, Lankhorst GJ, Beckerman H,
Bouter LM: Treating patients with hemiplegic shoulder pain. Am J Phys
Med Rehabil 2002;81:150–160.
Studies on the efficacy of available methods of treatment for hemiplegic
shoulder pain are reviewed in an attempt to identify the most effective
treatment for this problem. Because of the poor quality of the 14 se-
lected studies, no definite conclusion can be drawn about the most
effective method of treatment. However, functional electrical stimula-
tion and intra-articular triamcinolone acetonide injections seem to be
the most promising treatment options.
Key Words: Systematic Review, Stroke, Treatment, Hemiplegic
Shoulder Pain
Shoulder pain is a common problem after stroke; the occurrence reported
in the literature varies from 16 to 84%.1–8 Patients with hemiplegic shoulder
pain remain hospitalized longer, and shoulder pain complicates the rehabili-
tation process.2,7 Physicians and therapists from many different disciplines are
involved in the treatment of these patients, and many different methods of
treatment have been described and applied to patients with hemiplegic shoul-
der pain.1,9 Many different measures have also been recommended to prevent
hemiplegic shoulder pain.1–3,10–13
In recent decades, several reviews on hemiplegic shoulder pain have been
published.1,6,9,10,12,14 These reviews focus mainly on the etiology and treatment
of hemiplegic shoulder pain. In general, the causes of hemiplegic shoulder pain
can be divided into two categories: distant sources of (referred) shoulder pain
(e.g., neck problems, visceral referred pain, thalamic pain) and local problems
(e.g., rotator cuff disorders, adhesive capsulitis, subluxation of the glenohu-
meral joint, tendinitis, spasticity).1,6,9,12,14 Pain in the hemiplegic shoulder
may also be caused by shoulder-hand syndrome or reflex sympathetic dystro-
phy.6,10,12,14 From the reviews that have been published, no conclusion could
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be drawn about the most effective
method of treatment for hemiplegic
shoulder pain for the following rea-
sons. First, because they were not
systematic. Second, no attempt has
been made to estimate the method-
ological quality of the published stud-
ies, and third, success rates were not
always mentioned. Furthermore,
since the most recent review12 was
published, several interesting inter-
vention studies15–18 on hemiplegic
shoulder pain have been published.
In an attempt to identify the most
effective method of treatment for
hemiplegic shoulder pain, the litera-
ture was searched for studies that de-
scribe the results of an intervention
to treat hemiplegic shoulder pain.
METHODS
A search was made in MEDLINE
(from 1966 to October 1999), Embase
(from 1988 to September 1998), CI-
NAHL (from 1982 to September
1999), REHABDATA (from 1994 to
July 1999), and the Cochrane Library
(issue 2, 1999). The following key-
words were used: (1) hemiparesis,
hemiplegia, stroke, cerebrovascular
disorder, cerebrovascular disease,
brain injury, or brain ischemia; (2)
shoulder, arm, or upper extremity;
and (3) pain. For practical reasons,
only studies published in Dutch, En-
glish, French, or German were se-
lected. Further selection was based
on the title and abstract. Only studies
concerning the treatment of hemi-
plegic shoulder pain were included,
and pain had to be one of the out-
come measures. No restrictions were
made with regard to study design.
The references of the available arti-
cles were tracked for further possible
studies.
The selected studies were rated
for methodological quality indepen-
dently by two reviewers (I. Snels and
J. Dekker). One study was reviewed
by the third author (J. van der Lee)
because it was written by the second
author. The review process was not
blinded. The criteria list used to as-
sess the methodological quality of the
selected studies is presented in Table
1. Similar criteria have been used in
other reviews.19–22
Although most studies described
more than one outcome measure,
only the scores for the outcome pain
were taken into account in the calcu-
lation of the methodological score
(item 13). The methodological score
for each study was calculated by add-
ing the points for each item together,
the maximum possible score being 48
(100%). Thus, the higher the score,
the higher the quality. A score of zero
for an item meant that either the
information about that item was not
well described, or there was no in-
formation about it at all in the
publication.
Data on study design, study pop-
ulation, and intervention were ex-
tracted. If possible, success rates for
each treatment group were calcu-
lated as the percentage of patients
treated successfully (according to the
authors) divided by the total number
of patients allocated to that specific
treatment group (intention-to-treat).
RESULTS
Selected Studies
On the basis of both the title and
abstract, 25 articles were identified.
Of these, 11 articles were excluded for
the following reasons: in one study,
the intervention was diagnostic in-
stead of therapeutic;23 in two studies,
the outcome measures did not in-
clude pain;24,25 three studies dealt
with primary prevention;18,26,27 in
two studies, the intervention was
aimed at reducing spasticity instead
of pain;28,29 and three studies dealt
with reflex sympathetic dystrophy
and shoulder-hand syndrome instead
of hemiplegic shoulder pain.30–32
Reference tracking resulted in one
additional publication33 that met the
criteria; however, it referred to a
study by Caldwell et al.34 that had
already been selected, so the data of
these two articles were combined.
Fourteen studies met the inclu-
sion criteria and were rated for meth-
odological quality.15–17,33–44 Before
the consensus meeting, the reviewers
disagreed on 64 out of 672 items
(9.5%). Most disagreements between
the reviewers resulted from reading
errors and were easily resolved. The
final methodological score was deter-
mined by consensus. Table 2 presents
the study characteristics of the 14
studies, which are grouped according
to the aim of the intervention: (1)
normalization of muscle tone, (2) re-
duction of glenohumeral subluxa-
tion, and (3) treatment of the shoul-
der capsule. Within these three
groups, the various studies are
ranked in order of decreasing meth-
odological score.
The methodological scores ranged
from 2 to 25 of 48 (4–52% of the max-
imum score), indicating the overall
poor methodological quality. Eight
studies scored less than 10 points (21%
of the maximum score), two of which
were not even above the minimum
score of 2 points. This minimum score
of 2 points implies that only the type of
intervention is mentioned (1 point)
and that pain is an outcome measure
that is clinically relevant (1 point).
These factors were inherent to the in-
clusion criteria.
Table 2 shows that the success
rates vary from 0 to 100%. It was not
possible to calculate the success rate
for the interventions described in four
of the studies because the results were
only reported at group level17,39 or be-
cause the number of patients who were
treated successfully was not men-
tioned.41,43 As shown in Figure 1, suc-
cess rates are inversely related to meth-
odological quality. Only the success
rates in the studies carried out by Wil-
liams44 (52%), Chantraine et al.15
(67%) and Dekker et al.16 (46%) con-
form to an intention-to-treat analysis.
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Characteristics of Selected
Studies
As can be seen in Table 2, the
study designs of the selected studies
are very divergent. There are three ran-
domized clinical trials (RCTs),17,39,41
one randomized trial with a crossover
design,44 one controlled study (not
randomized),15 one multiple baseline
design,16 five case series,33,34,38,40,42,43
and three case reports.35–37 Of the four-
teen studies, two included more than
50 patients15,41 and five included
less than 10 patients.16,35–37,42 Nine
studies did not include a control
group.16,35–38,40,42,43
The characteristics of the study
populations are also presented in
TABLE 1
Criteria list used to assess the methodologic quality of intervention studies on hemiplegic
shoulder pain
Description of Items and Subitems Maximum Score
Study population
1 Selection of patients (at least two clear selection criteria are described) 1
2a Randomization or matching 1
2b Adequate description of the procedure 1
3 Comparability of the groups for the following prognostic variables:
(a) time since onset stroke; (b) baseline scores for pain; (c) age; (d) first or repeated stroke; (e)
neuropsychological problems (e.g., neglect) (f) type of stroke (infarction/hemorrhage, 1 point
for each variable)
6
4a Drop-outs described (definite and temporary; 1 point for each possibility) 2
4b Reasons for drop-out described 1
4c No bias because of drop-outs 1
4d e Percentage of drop-outs in experimental group described 1
4d c Percentage of drop-outs in control group described 1
5a Follow-up described 1
5b Duration of follow-up described 1
5c Number of relapses described 1
6a Loss to follow-up for each treatment group described 1
6b Reasons for loss to follow-up described 1
6c No bias occurred because of loss to follow-up 1
6d e Percentage of loss to follow-up in experimental group described 1
6d c Percentage of loss to follow-up in control group described 1
Interventions
7 In experimental group: (a) type of intervention; (b) intensity; (c) compliance described (1 point
for each aspect)
3
8 In control group: (a) type of intervention; (b) intensity; (c) compliance described (1 point for
each aspect)
3
9 Co-interventions in each group: (a) described; (b) similar in all groups (1 point for each item) 2
Blinding and outcome measurement
10a Attempt to blind patients 1
10b Blinding successful 1
11a Attempt to blind therapist/physician 1
11b Blinding successful 1
12a Attempt to blind observer of effect 1
12b Blinding successful 1
13 Outcome measurea: (a) clinically relevant; (b) reliable; (c) valid (1 point for each aspect) 3
14 Similar timing of outcome measurements in all treatment groups 1
Data presentation and analysis
15 Intention-to-treat analysis 1
16a Analysis between groups 1
16b Level of significance or confidence interval given 1
16c Correction for time-dependency for trends if necessary 1
17a Frequencies given 1
17b Mean and standard deviations given 1
17c Median given 1
Total 48
aThe outcome measure of interest is pain.
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Table 2. Many studies investigated
hemiplegic shoulder pain in pa-
tients with subacute and chronic
stroke.
Interventions
The interventions studied were
electromyographic (EMG) biofeed-
back,44 functional electrical stimula-
tion (FES),15,17 intra-articular triam-
cinolone acetonide injections,16
ultrasound,39 cryotherapy,41 sur-
gery,33,34,42 phenolization,35,38 audi-
tory feedback,37 sling,43 brace,40 and
splint jacket.36 In general, these in-
terventions were quite adequately de-
scribed (Table 2). The co-interven-
tions were either described in general
terms only15–17,34,35,37,38,40–42,44 or
not mentioned at all.36,39,43 The fol-
low-up period varied from 0 to 39 mo.
In four studies, the follow-up period
was not specified.35,36,40,43
Outcome Assessment
Pain was the outcome of interest
in the present review. To estimate the
effect of an intervention on pain, it
must be clear how the pain was as-
sessed. Williams44 used the validated
McGill Pain Questionnaire, and Dek-
ker et al.16 used a visual analog scale,
which has also been validated. Chant-
raine et al.15 also used a visual analog
scale, but they combined this scale
with other pain measures that were
not well described, and no results
were reported for the separate pain
measures. Partridge et al.41 used sev-
eral 4–6 point scales, but they pro-
vided no information about the clini-
metric properties. Hecht38 described
which patient reactions were used to
rate the pain. This method seems, at
least, to have some face validity. The
range of motion does not seem to be a
valid instrument with which to mea-
sure pain.17 In the other studies, pain
was assessed directly from the reac-
tions of the patients,33,34,36,37,39,42,43 on
the basis of a therapist’s interpretation
of the reactions of the patients,38 or
there was no description of how the
pain was assessed.35
Results of the Interventions
Interventions Aimed at Normaliza-
tion of Muscle Tone. The randomized
crossover trial investigating the effect
of EMG biofeedback combined with
relaxation exercises attained the
highest methodological score and
had a success rate after 2 wk of 50–
60%.44 Because both methods of
treatment are applied without a
wash-out period, it is impossible to
calculate the success rate for each
separate treatment. The follow-up pe-
riod was also different for the two
groups. Another method which is
used to reduce spasticity is phenol-
ization. This treatment was applied in
two studies, with a success rate of
83% in a case series study38 and
100% in a case report study.35 Cryo-
therapy is a third method that is ap-
plied to reduce pain and spasticity.45
Partridge et al.41 found no beneficial
effects of cryotherapy compared with
the Bobath approach to the hemiple-
gic shoulder.
Interventions Aimed at Reducing
Subluxation. In a controlled non-
randomized trial,15 compared with
patients in a control group who re-
ceived no (additional) FES therapy,
more patients with FES were without
pain at 3 and 24 mo posttreatment:
36% vs. 70% and 55% vs. 81%, re-
spectively. In an RCT, no significant
effect of FES was found at 12 wk.17
Surgery was used to reduce sub-
luxation, with success rates of 77–
83%.33,34,42 The surgery was followed
by exercises and a sling. Other meth-
ods applied in studies to reduce sub-
luxation were a Varney brace,40
sling,43 auditory feedback37 and a
splint jacket.36 All of these methods
resulted in success rates of 90–100%.
The methodological score of all stud-
ies investigating the effect of surgery
or shoulder supports was below 10
points (21%).
Interventions Aimed at Treatment of
the Shoulder Capsule. A third cate-
gory of possible treatments for hemi-
plegic shoulder pain focuses on the
shoulder capsule. The effect of intra-
articular triamcinolone acetonide in-
jections as treatment for capsulitis
(as a cause for hemiplegic shoulder
pain) was investigated in one study.16
The success rate of this treatment
was 56%. Contractures of the shoul-
der resulting from capsular tightness
can also be treated with ultrasound.39
No effect was found for a 4-wk period
Figure 1: Success rate in relation to methodological score of 10 studies. Only
the success rates of Williams44 (52%), Chantraine et al.15 (67%), and Dekker
et al.16 (46%) are according to intention-to-treat analysis.
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of ultrasound treatment with regard
to range of motion in the shoulder.
Direct assessment of pain (protective
reactions and complaints of patients)
yielded insufficient data for analysis
of the change in pain. Indirect assess-
ment of pain (range of motion)
showed no differences between the
intervention and the control
groups.39
DISCUSSION
Fourteen studies were identified
during the literature search, and it
seems unlikely that any important
publication was missed during this
thorough search. However, it is pos-
sible that relevant studies remained
unpublished or have been published
in journals that are difficult to re-
trieve. The design of the selected
studies was very divergent and
ranged from case reports36,37 to
RCTs.17,39,41 RCTs provide the most
convincing results with regard to the
evaluation of interventions.46,47 Case
reports, on the other hand, are not
considered to be convincing at all. To
make it possible to compare the
methodological quality of studies
with such diverse designs, a very de-
tailed criteria list was used. Although
it is difficult to attain the maximum
score of 48 points, it was disappoint-
ing that the study with the best
methodological quality only scored
25 points (52%). Eight studies scored
less than 10 points, two of which
were not even above the minimum
score of 2 points. Thus, the method-
ological quality of the selected stud-
ies was found to be poor. In many
cases, there was insufficient or inad-
equate information about the study
population; the duration of the
shoulder pain; the exact intervention;
blinding of the patient, therapist, and
the observer of the effect; dropouts;
follow-up; co-interventions; and sta-
tistical methods. This could have
been the result of poor reporting, but
it probably indicates real shortcom-
ings in study design and execution.
Surprisingly, the three studies
with the highest methodological
score15,16,44 were not the three
RCTs.17,39,41 The reason for this is
probably that no weight factors
were assigned to the items on the
detailed criteria list. Therefore
random treatment allocation and
masked outcome assessment were
relatively underscored.
Adequately concealed treatment
allocation and masked outcome as-
sessment have been shown to de-
crease the estimate of the treatment
effect in meta-analyses of RCTs,48–50
including low-quality RCTs in meta-
analyses, which increase the overall
estimate of the treatment effect by
30–50%.49,50 The three RCTs17,39,41
had major methodological shortcom-
ings, and it is therefore possible that
the success rates found in these stud-
ies are overestimated.
The review process was not
blinded. From meta-analyses of
RCTs, it is known that masked assess-
ments, compared with unmasked as-
sessments, of the methodological
quality of studies sometimes result in
different scores.49,51 However, Verha-
gen et al.52 showed in their study that
there was little difference between
blinded assessment and unblinded as-
sessment, and masking assessment
did not change the overall conclusion
of a meta-analysis of five RCTs.53
Evaluation of the Interventions
Interventions Aimed at Normaliza-
tion Muscle Tone. Several methods
for reducing spasticity were investi-
gated. The study combining EMG
biofeedback and relaxation exercises
had the best methodological score.44
However, both methods of treatment
are applied without a wash-out pe-
riod, so it is impossible to draw sep-
arate conclusions about the individ-
ual effects of EMG biofeedback and
relaxation exercises. The combina-
tion seems to be successful, regard-
less of the order in which these treat-
ments are applied. However, the
question of whether these methods of
treatment are better than no treat-
ment at all, or placebo EMG biofeed-
back, remains unanswered. More-
over, the follow-up period was very
short and was not the same for both
groups.44 In our opinion, the au-
thor’s conclusion, that there is a
trend that EMG biofeedback reduces
pain, is not supported by the results
presented in her publication.
The RCT on the effect of cryo-
therapy vs. the Bobath approach re-
mains inconclusive because, accord-
ing to the authors’ references,
cryotherapy should be applied to re-
duce pain and spasticity, but 22 pa-
tients out of the 65 who completed
the treatment suffered from flaccid-
ity, and six patients had normal to-
nus. Moreover, 20 patients dropped
out before the end of the treatment
period.
The effect of phenol is described
in two studies that were of poor
methodological quality, so no con-
clusions can be drawn about its effec-
tiveness.35,38 Botulinum toxin28 and a
wrapping technique are other meth-
ods of treatment that are applied to
reduce spasticity,29 but these studies
were excluded from our review.
Interventions Aimed at Reducing
Subluxation. FES was investigated in
two studies. In both studies, the con-
trol group received no (additional)
FES therapy.15,17 In the non-random-
ized controlled study, more patients
in the intervention group than in the
control group were without pain at 3
and 24 mo posttreatment.15 In the
RCT, after 12 wk no differences were
found between the groups.17 Because
the control groups received no sham
FES, it is possible that the effects of
FES are simply nonspecific.
Other techniques used to reduce
subluxation are surgery,33,34,42 Var-
ney brace,40 sling,43 auditory feed-
back,37 and a splint jacket.36 No con-
clusions about the effectiveness of
any of these techniques can be drawn
because of the poor methodological
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quality of the relevant studies. Ac-
cording to Hurd et al.,26 hemiplegic
shoulder pain cannot be prevented by
a sling. Although a considerable
amount of effort is being invested in
finding a relationship between sub-
luxation of the hemiplegic shoulder
and shoulder pain, no such relation-
ship has yet been found.54
Interventions Aimed at Treatment of
the Shoulder Capsule. Corticosteroid
injections have been shown to be ef-
fective in the treatment of capsulitis
of the shoulder.21,55,56 The signs and
symptoms of hemiplegic shoulder
pain are similar to those found in a
nonhemiplegic painful shoulder (cap-
sulitis adhaesiva).57 Triamcinolone
acetonide injections seem to be a
promising intervention for hemiple-
gic shoulder pain.16
Ultrasound is thought to reveal
pain from joint contractures result-
ing from capsular tightness, scarring,
and sprains in a nonhemiplegic
shoulder. In an RCT, no effect of ul-
trasound on hemiplegic shoulder
pain was found.39 Vasodilatation in-
duced by transcutaneous electrical
nerve stimulation is reported to re-
duce myofascial pain, such as hemi-
plegic shoulder pain.24
CONCLUSIONS
Although the success rates seem
impressive (up to 100%), the meth-
odological quality of the reviewed
studies was moderate to poor. It is
therefore concluded that none of the
results are convincing enough to pro-
vide an answer to the question of
which treatment is most effective for
patients with hemiplegic shoulder
pain. Further research is needed not
only to find the best methods to pre-
vent hemiplegic shoulder pain but
also to find the most effective treat-
ment for this problem. This research
should be directed toward preventive
measures and methods of treatment
that are the least aggressive and seem
to be biologically plausible and the
most promising (on the basis of
present knowledge). All research
should be based on high methodolog-
ical standards, and therefore, RCTs
are recommended. The authors sug-
gest that the most promising meth-
ods of treatment for further research
at this stage are FES and intra-artic-
ular triamcinolone acetonide injec-
tions. Phenol injections seem to be
biologically plausible for the treat-
ment of muscle hypertonia.
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